在手术前使用ondansetron片剂预防手术后恶心和吐,用于接受眼手术的儿科患者:一项随机对照试验
Saad A Moharam1, Mohammed S Elsharkawy2, Shaimaa W Zahra2
1Department of Anesthesiology, Surgical Intensive Care and Pain Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt - saad.moharam@med.tanta.edu.eg.
Minerva anestesiologica
|February 5, 2026
概括
在小儿眼手术患者中,手术前使用的安丹塞特龙药片显著降低了手术后恶心和吐 (PONV). 这种干预措施还降低了PONV的严重程度,提高了家长的满意度.
科学领域:
- 麻醉学 麻醉学
- 儿科手术 儿科手术
- 药理学 药理学是指药理学的学科.
背景情况:
- 手术后恶心和吐 (PONV) 是小儿眼手术的一个重大挑战.
- 在儿童中,PONV会导致严重的并发症.
- 需要有效的预防策略来管理这个人群中的PONV.
研究的目的:
- 为了评估手术前的丹塞特朗药片在预防PONV的疗效,在接受眼手术的儿科患者.
- 为了比较Ondansetron和对照组之间的PONV发病率和严重程度.
主要方法:
- 一项随机对照试验,涉及80名儿童患者 (4至15岁) 接受眼手术.
- 患者被分配到接受手术前的4毫克丹松药片或对照治疗.
- 评估了PONV发病率,严重程度,吐时间,眼心反射和家长满意度.
主要成果:
- 丹塞组的PONV发病率显著降低 (22.5%与52.5%,P=0.006).
- 在所有测量间隔和延长吐时间 (P=0.005) 中,Ondansetron降低了PONV的严重程度.
- 眼心反射的发生率较低 (12.5%对37.5%,P=0.018),父母的满意度在丹塞组更高 (P=0.004).
结论:
- 在手术前使用的丹塞特龙药片有效地减少了儿科眼手术中PONV的发病率和严重程度.
- 这种干预也可以缓解诸如眼心反射等并发症.
- 丹塞特朗软代表了在儿科眼科手术中对PONV的有前途的预防策略.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
790
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
790
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
681
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
681
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
890
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
890
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
627
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
627
Pathophysiology of Vomiting
3.1K
Vomiting is a complex physiological response to expel harmful or irritating substances from the body. It's a defensive mechanism triggered by stimuli like poisons, microbial toxins, cytotoxic drugs, and mechanical abdominal distension. The process is centrally coordinated by the vomiting (or emetic) center located in the medulla of the brainstem. This area, rich in muscarinic M1, histamine H1, neurokinin 1 (NK1), and serotonin 5-HT3 receptors, coordinates the act of vomiting through...
3.1K
Clinical Trials: Overview
5.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K


